biocompatible peritoneal dialysis fluids clinical outcomes生物相容性的腹膜透析液的临床结果.pdfVIP

Hindawi Publishing Corporation International Journal of Nephrology Volume 2012, Article ID 812609, 9 pages doi:10.1155/2012/812609 Review Article Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes Yeoungjee Cho,1 Sunil V. Badve,1 Carmel M. Hawley,1 Kathryn Wiggins,2 and David W. Johnson1 1 Department of Nephrology, Princess Alexandra Hospital, University of Queensland, Level 2, ARTS Building, 199 Ipswich Road, Woolloongabba, Brisbane QLD 4102, Australia 2 Department of Nephrology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia Correspondence should be addressed to Sunil V. Badve, sunil badve@.au Received 31 July 2012; Accepted 19 October 2012 Academic Editor: Wai-Kei Lo Copyright © 2012 Yeoungjee Cho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Peritoneal dialysis (PD) is a preferred home dialysis modality and has a number of added advantages including improved initial patient survival and cost effectiveness over haemodialysis. Despite these benefits, uptake of PD remains relatively low, especially in developed countries. Wider implementation of PD is compromised by higher technique failure from infections (e.g., PD peritonitis) and ultrafiltration failure. These are inevitable consequences of peritoneal injury, which is thought to result primarily from continuous exposure to PD fluids that are characterised by their “unphysiologic” composition. In order to overcome these barriers, a number of more biocompatible PD fluids, with neutral pH, low glucose degradation product content, and bicarbonate buffer have been manufactured over the past two decades. Seve